Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

导出 LinkOut

翻译打印收藏纠错

作者： Beverly L,Falcon ^[1] ; Sudhakar,Chintharlapalli ^[1] ; Mark T,Uhlik ^[2] ; Bronislaw,Pytowski ^[3]

作者单位： Eli Lilly and Company, Indianapolis, IN, USA. ^[1] Biothera, Eagan, MN, USA. ^[2] Eli Lilly and Company, New York, NY, USA. Electronic address: bronek.pytowski@lilly.com. ^[3]

关键词 Angiogenesis DC101 Endothelial cell Ramucirumab Tumor vasculature VEGFR-2

主题词动物(Animals);抗体, 单克隆(Antibodies, Monoclonal);抗药性, 肿瘤(Drug Resistance, Neoplasm);药物疗法, 联合(Drug Therapy, Combination);人类(Humans);肿瘤(Neoplasms);新生血管化, 病理性(Neovascularization, Pathologic);血管内皮生长因子受体2(Vascular Endothelial Growth Factor Receptor-2)

DOI 10.1016/j.pharmthera.2016.06.001

PMID 27288725

发布时间 2023-12-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览53

Pharmacology & therapeutics

2016年164卷

204-25页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

Pharmacology & therapeutics

相似文献

Pharmacology & therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents.

Pharmacology & therapeutics

相似文献

Pharmacology & therapeutics

相关期刊

检索历史清除